Evidence map›Paper›PMID 29437466›Full record

ArticleAmerican journal of respiratory and critical care medicine2018

Gene Promoter Hypermethylation Detected in Sputum Predicts FEV

Shuguang Leng, Brenda Diergaarde, Maria A Picchi, David O Wilson, Frank D Gilliland, Jian-Min Yuan, Jill M Siegfried, Steven A Belinsky

Abstract read
In one paragraph

Article in American journal of respiratory and critical care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. DNA Methylation Is Predictive of Mortality in Current and Former Smokers.American journal of respiratory and critical care medicine · 2020
    Article
  8. Update in Chronic Obstructive Pulmonary Disease 2018.American journal of respiratory and critical care medicine · 2019
    Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Shuguang Leng1 Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Brenda Diergaarde4 Department of Human Genetics and.
Maria A Picchi1 Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
David O Wilson7 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Frank D Gilliland8 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; and.
Jian-Min Yuan9 Department of Epidemiology, Graduate School of Public Health, and.
Jill M Siegfried5 Cancer Epidemiology and Prevention Program.
Steven A Belinsky1 Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Lovelace Respiratory Research Institute · USPrevention Institute · USQingdao University · CNUniversity of Pittsburgh · USUniversity of Southern California · USUPMC Hillman Cancer Center · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
Vitamin D3 Modulation of Inflammation and Lung Cancer RiskP50CA090440 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SIEGFRIED, JILL M · 2001 to 2015
$34.6M
Factors for Epigenetic Silencing of Lung Cancer GenesR01CA097356 · NCI · LOVELACE BIOMEDICAL & ENVIRONMENTAL RESEARCH INSTITUTE · PI BELINSKY, STEVEN A · 2004 to 2014
$6.3M
Epigenetic Changes Link COPD and Lung CancerR01CA164782 · NCI · LOVELACE BIOMEDICAL & ENVIRONMENTAL RESEARCH INSTITUTE · PI BELINSKY, STEVEN A, TESFAIGZI, YOHANNES · 2011 to 2014
$3.2M
NCI NIH HHS P30 CA047904NCI NIH HHS P30 CA118100NCI NIH HHS P50 CA090440NCI NIH HHS R01 CA097356NCI NIH HHS R01 CA164782
6 · The paper itself

Abstract

rationaleGene promoter hypermethylation detected in sputum assesses the extent of field cancerization and predicts lung cancer (LC) risk in ever-smokers. A rapid decline of FEV

objectivesTo assess the effects of methylation of 12 genes on FEV

methodsGene methylation was measured in sputum using two-stage nested methylation-specific PCR. The linear mixed effects model was used to assess the effects of studied variables on FEV MEASUREMENTS AND MAIN

resultsA dose-dependent relationship between number of genes methylated and FEV

conclusionsGene methylation detected in sputum predicted FEV

Indexed as

Genetic Predisposition to DiseasePromoter Regions, GeneticAdultAgedAged, 80 and overCohort StudiesDNA MethylationFemaleGenetic TestingHumansLung NeoplasmsMaleMiddle AgedRespiratory Function TestsRisk FactorsSmokingcause of deathepigeneticslongitudinal studieslung neoplasmsspirometry

Identifiers

PMID29437466
PMCPMC6058990
OpenAlexW2793455106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.